
Daniel Soffer
Clinical lipidologist and Associate Professor of Clinical Medicine at Penn Medicine; former President of the National Lipid Association.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
Sep 7, 2026
The Case for Treating Cholesterol Before Plaque Appears | Dr Thomas Dayspring and Dr Dan Soffer
1:17
1:23
1:39
53:29

Daniel SofferGUEST
I, I imagine there are humans that don't have any shred of it, but I don't think we have a really way to know that.

Daniel SofferGUEST
We can assume that we all are developing atherosclerosis to some degree, but that the rate that we develop that condition varies tremendously between individuals and based upon a lot of different factors.

Daniel SofferGUEST
We have talked in the past, and I know Tom has given treatise on this as well, about the atherogenesis process, like how atherosclerosis forms.
52 MINS LATER

Simon HillHOST
At a high level, how does this new set of guidelines differ from older ones in terms of the primary prevention, this conversation we're having specifically, uh, related to kind of acting earlier? What's different about these guidelines?